-DOCSTART- O

The	O
high-resolution	O
X-ray	O
diffraction	O
reciprocal	O
space	O
mapping	O
(	O
RSM	O
)	O
of	O
the	O
strain-free	O
solar	O
cell	O
sample	O
was	O
analyzed	O
by	O
an	O
X-ray	B-DEV
diffractometer	I-DEV
(	O
Philips	B-BRAND
X'pert	I-BRAND
,	O
PANalytical	B-COM
B.V.	I-COM
,	O
Almelo	O
,	O
The	O
Netherlands	O
)	O
.	O

Rapid	O
thermal	O
annealing	O
is	O
performed	O
on	O
four	O
samples	O
in	O
N	O
2	O
ambient	O
in	O
the	O
temperature	O
range	O
of	O
700	O
°C	O
to	O
850	O
°C	O
for	O
2	O
min	O
.	O

Images	O
were	O
acquired	O
using	O
a	O
Biospec	B-DEV
tomograph	I-DEV
(	O
Bruker	B-COM
,	O
Karlsruhe	O
,	O
Germany	O
)	O
equipped	O
with	O
a	O
4.7	O
Tesla	O
(	O
T	O
)	O
,	O
33-cm	O
bore	O
horizontal	O
magnet	B-DEV
(	O
Oxford	B-COM
Ltd.	I-COM
,	O
Oxford	O
,	O
United	O
Kingdom	O
)	O
.	O

Axial	O
multislice	O
fast	O
Spin	O
Echo	O
T2-weighted	O
(	O
RARE	O
,	O
TE	O
Eff	O
Images	O
were	O
acquired	O
before	O
and	O
at	O
t	O
1/4	O
10.5	O
min	O
,	O
21	O
min	O
,	O
and	O
31.5	O
min	O
after	O
injection	O
of	O
the	O
Gd-DTPA	O
(	O
MagnevistV	B-BRAND
R	I-BRAND
,	O
Schering	B-COM
,	O
Germany	O
)	O
at	O
300	O
mmol/kg	O
dosage	O
.	O

PFGE	O
patterns	O
were	O
compared	O
using	O
published	O
standard	O
criteria	O
,	O
and	O
analyzed	O
by	O
BioNumerics	B-BRAND
software	B-DEV
(	O
Version	O
4.0	O
,	O
Applied	B-COM
Maths	I-COM
BVBA	I-COM
,	O
Belgium	O
)	O
.	O

Pulsotypes	O
differed	O
by	O
six	O
fragments	O
or	O
less	O
were	O
grouped	O
into	O
one	O
cluster	O
.	O

Total	O
RNA	O
was	O
isolated	O
with	O
the	O
PAXgene	B-BRAND
blood	B-DEV
RNA	I-DEV
kit	I-DEV
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

The	O
manufacturer	O
's	O
protocol	O
was	O
modified	O
by	O
extending	O
the	O
proteinase	O
K	O
treatment	O
time	O
to	O
35	O
min	O
.	O

After	O
processing	O
,	O
the	O
specimens	O
were	O
polished	O
using	O
a	O
polishing	B-DEV
machine	I-DEV
(	O
Metaserv	B-BRAND
2000	I-BRAND
,	O
Bö	B-COM
ehler	I-COM
,	I-COM
UK	I-COM
,	I-COM
Ltd	I-COM
,	O
Coventry	O
,	O
UK	O
)	O
to	O
a	O
final	O
dimension	O
of	O
65	O
·	O
10	O
·	O
3.3	O
mm	O
,	O
according	O
to	O
the	O
International	O
Organization	O
for	O
Standardization	O
(	O
ISO/FDIS	O
1567	O
)	O
.	O

The	O
cell	O
pellet	O
was	O
resuspended	O
in	O
100	O
ml	O
of	O
Annexin-V-FLUOS	B-BRAND
labeling	O
solution	O
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
,	O
containing	O
20	O
ml/ml	O
of	O
Annexin-V-FLUOS	B-BRAND
labeling	O
reagent	O
and	O
20	O
ml/ml	O
of	O
propidium	O
iodide	O
(	O
PI	O
)	O
solution	O
.	O

Descriptive	O
statistics	O
(	O
e.g.	O
means	O
and	O
proportions	O
)	O
were	O
derived	O
using	O
QPSMR	B-BRAND
Reflect	I-BRAND
Version	I-BRAND
2007.1	I-BRAND
g	I-BRAND
(	O
QPSMR	B-COM
Ltd.	I-COM
,	O
Wallingford	O
,	O
UK	O
)	O
.	O

Results	O
Physician	O
and	O
patient	O
respondents	O
A	O
total	O
of	O
1214	O
physicians	O
were	O
contacted	O
and	O
348	O
(	O
29	O
%	O
)	O
participated	O
in	O
the	O
survey	O
.	O

Paisley	O
,	O
UK	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
,	O
purified	O
with	O
QIAGEN	B-COM
's	O
RNeasy	B-BRAND
Total	O
RNA	B-DEV
Isolation	I-DEV
kit	I-DEV
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
and	O
quantified	O
using	O
Nanodrop	B-BRAND
ND-1000	I-BRAND
.	O

The	O
quality	O
of	O
the	O
RNA	O
was	O
assessed	O
by	O
agaroseformaldehyde	O
gel	O
electrophoresis	O
.	O

The	O
samples	O
were	O
placed	O
in	O
an	O
oven	B-DEV
(	O
Memmert	B-COM
GmbH	I-COM
+	I-COM
CO.KG	I-COM
,	O
Schwabach	O
,	O
Germany	O
)	O
at	O
105	O
°C	O
for	O
21	O
h	O
,	O
after	O
which	O
the	O
samples	O
were	O
removed	O
and	O
weighed	O
.	O

Statistical	O
analysis	O
Statistical	O
analyses	O
were	O
performed	O
using	O
MINITAB	B-BRAND
16	I-BRAND
software	B-DEV
(	O
Minitab	B-COM
Ltd.	I-COM
,	O
Coventry	O
,	O
UK	O
)	O
.	O

Incubation	O
period	O
and	O
immunofluorescence	O
analysis	O
quantification	O
data	O
were	O
tested	O
for	O
equal	O
variances	O
and	O
analysed	O
by	O
two-sample	O
t-test	O
.	O

The	O
engineered	O
peptide	O
was	O
synthesized	O
by	O
JPT	B-COM
Peptide	I-COM
Technologies	I-COM
GmbH	I-COM
(	O
Berlin	O
,	O
10	O
Germany	O
)	O
.	O

Peptide	O
treatments	O
were	O
performed	O
for	O
2h	O
at	O
37ºC	O
with	O
orbital	O
agitation	O
,	O
50rpm	O
.	O

During	O
the	O
first	O
postoperative	O
week	O
,	O
the	O
infants	O
received	O
a	O
silicone	B-DEV
contact	I-DEV
lens	I-DEV
(	O
Silflex	B-BRAND
,	O
Wöhlk	B-COM
Kontaktlinsen	I-COM
GmbH	I-COM
,	O
Kiel	O
,	O
Germany	O
)	O
for	O
optical	O
correction	O
,	O
with	O
the	O
exception	O
of	O
patient	O
1	O
,	O
who	O
received	O
primary	B-DEV
intraocular	I-DEV
lens	I-DEV
implantation	I-DEV
(	O
AcrySof	B-BRAND
lens	I-BRAND
,	O
Alcon	B-COM
,	B-COM
Inc.	I-COM
,	O
Fort	O
Worth	O
,	O
TX	O
)	O
in	O
both	O
eyes	O
.	O

The	O
PARP-1	O
zinc	O
binding	O
domain	O
(	O
GRASCKKCSESIPKDSLRMAIMVQSPMFDGKVPHWYHFSCFWKV	O
)	O
was	O
purchased	O
from	O
Peptide	B-COM
Specialty	I-COM
Laboratories	I-COM
GmbH	I-COM
(	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Dithiothreitol	O
(	O
DTT	O
;	O
molecular	O
biology	O
grade	O
)	O
and	O
zinc	O
acetate	O
dihydrate	O
(	O
p.a.	O
)	O
were	O
obtained	O
from	O
Sigma-Aldrich	B-COM
.	O

Peroxidase-conjugated	O
donkey	O
anti-goat	O
Ab	O
(	O
Dianova	B-COM
GmbH	I-COM
,	O
Hamburg	O
,	O
Germany	O
)	O
dissolved	O
in	O
PBS	O
containing	O
5	O
%	O
milk	O
powder	O
and	O
0.1	O
%	O
Tween-20	O
(	O
0.16	O
μg/mL	O
,	O
10	O
mL	O
)	O
was	O
then	O
added	O
to	O
the	O
membrane	O
.	O

Thermogravimetric	O
analysis	O
TGA	O
of	O
USPIONs	O
was	O
carried	O
out	O
using	O
a	O
STA	B-BRAND
409	I-BRAND
TGA	B-DEV
analyzer	I-DEV
(	O
Netzsch	B-COM
GmbH	I-COM
,	O
Selb	O
,	O
Germany	O
)	O
.	O

In	O
a	O
typical	O
TGA	O
run	O
,	O
5	O
to	O
10	O
mg	O
of	O
USPIONs	O
were	O
weighed	O
into	O
a	O
clay	O
sample	O
holder	O
and	O
the	O
sample	O
was	O
heated	O
from	O
50	O
to	O
650	O
°C	O
at	O
a	O
heating	O
rate	O
of	O
10	O
°C	O
/	O
min	O
in	O
ambient	O
atmosphere	O
.	O

During	O
preparation	O
,	O
the	O
synovial	B-DEV
membrane	I-DEV
was	O
sharply	O
removed	O
from	O
the	O
fibrous	O
tissue	O
of	O
the	O
capsule	O
The	O
tissue	O
was	O
cleared	O
from	O
blood	O
and	O
fat	O
using	O
phosphate-buffered	O
saline	O
(	O
PBS	O
,	O
Dulbecco	B-BRAND
's	B-BRAND
Phosphate	I-BRAND
Buffered	I-BRAND
Saline	I-BRAND
,	O
Sigma-Aldrich	B-COM
Chemie	I-COM
GmbH	I-COM
,	O
Steinheim	O
,	O
Germany	O
)	O
and	O
digested	O
in	O
a	O
water	O
bath	O
at	O
37	O
°C	O
with	O
a	O
mixture	O
of	O
type	O
IV	O
collagenase	O
(	O
1	O
mg/ml	O
,	O
Sigma-Aldrich	B-COM
Chemie	I-COM
GmbH	I-COM
,	O
Steinheim	O
,	O
Germany	O
)	O
,	O
trypsin	O
(	O
2.5	O
mg/ml	O
,	O
Sigma-Aldrich	B-COM
Chemie	I-COM
GmbH	I-COM
,	O
Steinheim	O
,	O
Germany	O
)	O
,	O
and	O
DNase	O
I	O
(	O
2	O
mg/ml	O
,	O
Applichem	B-COM
GmbH	I-COM
,	O
Darmstadt	O
,	O
Germany	O
)	O
.	O

The	O
heart	O
rate	O
was	O
continuously	O
recorded	O
telemetrically	O
(	O
Sport	B-BRAND
Tester	I-BRAND
S	I-BRAND
410	I-BRAND
,	O
RS	O
400	O
,	O
Polar	B-COM
Electro	I-COM
,	I-COM
Oy	I-COM
,	O
Kempele	O
,	O
Finland	O
)	O
.	O

The	O
probands	O
had	O
their	O
lipid	O
and	O
anthropometrical	O
parameters	O
and	O
blood	O
pressure	O
determined	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

We	O
evaluated	O
the	O
extended	O
data	O
from	O
55	O
unrelated	O
patients	O
,	O
26	O
from	O
the	O
present	O
study	O
and	O
29	O
from	O
previous	O
reports	O
from	O
Korea	O
,	O
9-21	O
and	O
compared	O
the	O
data	O
with	O
three	O
studies	O
from	O
the	O
literature	O
that	O
provided	O
a	O
spectrum	O
of	O
VHL	O
gene	O
mutations	O
in	O
Japan	O
7,22	O
and	O
China	O
.	O

8	O
The	O
data	O
for	O
the	O
phenotype	O
of	O
17	O
patients	O
previously	O
reported	O
were	O
also	O
reviewed	O
for	O
this	O
study	O
.	O

11,16	O
We	O
also	O
compared	O
the	O
data	O
from	O
East	O
Asian	O
countries	O
with	O
those	O
from	O
Western	O
countries	O
,	O
including	O
North	O
America	O
and	O
Europe	O
.	O

7,23,24	O
With	O
regard	O
to	O
its	O
clinical	O
manifestations	O
,	O
VHL	O
is	O
classified	O
into	O
two	O
types	O
:	O
type	O
1	O
is	O
without	O
pheochromocytoma	O
and	O
type	O
2	O
is	O
with	O
pheochromocytoma	O
.	O

25	O
In	O
addition	O
,	O
type	O
2	O
VHL	O
disease	O
is	O
subdivided	O
into	O
three	O
categories	O
depending	O
on	O
the	O
absence	O
of	O
RCC	O
(	O
type	O
2A	O
)	O
,	O
presence	O
of	O
RCC	O
(	O
type	O
2B	O
)	O
and	O
sole	O
manifestation	O
of	O
pheochromocytoma	O
without	O
HAB	O
or	O
RCC	O
(	O
type	O
2C	O
)	O
.	O

26	O
DNA	O
sequencing	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
leukocytes	O
using	O
a	O
QIAamp	B-BRAND
DNA	B-DEV
Blood	I-DEV
Mini	I-DEV
Kit	I-DEV
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Each	O
rotorod	O
had	O
two	O
wings	O
,	O
and	O
on	O
each	O
wing	O
a	O
transparent	B-DEV
microscope	I-DEV
glass	I-DEV
slide	I-DEV
(	O
Microscopes	B-COM
Plus	I-COM
Ltd.	I-COM
,	O
Hertfordshire	O
,	O
UK	O
)	O
and	O
a	O
double-sided	O
sticky	O
tape	O
were	O
attached	O
(	O
Fig.	O
1	O
)	O
.	O

Following	O
tomographic	O
imaging	O
,	O
the	O
brain	O
was	O
coronally	O
sectioned	O
at	O
50	O
lm	O
using	O
a	O
freezing	B-DEV
microtome	I-DEV
(	O
Microm	B-BRAND
HM450	I-BRAND
,	O
Microm	B-COM
Gmbh	I-COM
,	O
Waldorf	O
,	O
Germany	O
)	O
.	O

Every	O
fourth	O
section	O
was	O
stained	O
for	O
myelin	O
using	O
a	O
standard	O
procedure	O
modified	O
from	O
Woelche	O
-LSB-	O
Woelche	O
,	O
1942	O
-RSB-	O
.	O


